Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 May;61(5):414–421. doi: 10.1136/ard.61.5.414

Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome

F Williams 1, S Chinn 1, G Hughes 1, R Leach 1
PMCID: PMC1754095  PMID: 11959765

Abstract

Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both.

Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival.

Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%.

Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival.

Full Text

The Full Text of this article is available as a PDF (133.5 KB).

Figure 1 .

Figure 1

Open in a new tab

Frequency of diagnostic categories on admission for (A) primary and (B) accompanying diagnoses. CVS, cardiovascular; Inf , infection; Coag, coagulopathy; Neuro/other, neurological and other conditions.

Figure 2 .

Figure 2

Open in a new tab

Kaplan-Meier survival curves for patients with and without renal failure (A) by age and (B) by time since first ICU admission.

Figure 3 .

Figure 3

Open in a new tab

Kaplan-Meier survival curves for patients with and without infection on admission (A) by age and (B) by time since first ICU admission.

Figure 4 .

Figure 4

Open in a new tab

Kaplan-Meier survival curves for patients with and without APS (A) by age and (B) by time since first ICU admission.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Shakra M., Urowitz M. B., Gladman D. D., Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995 Jul;22(7):1259–1264. [PubMed] [Google Scholar]
  2. Ansell S. M., Bedhesi S., Ruff B., Mahomed A. G., Richards G., Mer M., Feldman C. Study of critically ill patients with systemic lupus erythematosus. Crit Care Med. 1996 Jun;24(6):981–984. doi: 10.1097/00003246-199606000-00018. [DOI] [PubMed] [Google Scholar]
  3. Asherson R. A. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992 Apr;19(4):508–512. [PubMed] [Google Scholar]
  4. Cervera R., Khamashta M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Doménech I., Aydintug A. O., Jedryka-Góral A., de Ramón E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993 Mar;72(2):113–124. [PubMed] [Google Scholar]
  5. Drenkard C., Villa A. R., Alarcón-Segovia D., Pérez-Vázquez M. E. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol. 1994 Jun;21(6):1067–1072. [PubMed] [Google Scholar]
  6. Ginzler E. M., Diamond H. S., Weiner M., Schlesinger M., Fries J. F., Wasner C., Medsger T. A., Jr, Ziegler G., Klippel J. H., Hadler N. M. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 1982 Jun;25(6):601–611. doi: 10.1002/art.1780250601. [DOI] [PubMed] [Google Scholar]
  7. Gladman D. D. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 1996 Sep;8(5):430–437. doi: 10.1097/00002281-199609000-00007. [DOI] [PubMed] [Google Scholar]
  8. Godeau B., Boudjadja A., Dhainaut J. F., Schlemmer B., Chastang C., Brunet F., Le Gall J. R. Outcome of patients with systemic rheumatic disease admitted to medical intensive care units. Ann Rheum Dis. 1992 May;51(5):627–631. doi: 10.1136/ard.51.5.627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Greisman S. G., Thayaparan R. S., Godwin T. A., Lockshin M. D. Occlusive vasculopathy in systemic lupus erythematosus. Association with anticardiolipin antibody. Arch Intern Med. 1991 Feb;151(2):389–392. [PubMed] [Google Scholar]
  10. Harris E. N., Pierangeli S. S., Gharavi A. E. Diagnosis of the antiphospholipid syndrome: a proposal for use of laboratory tests. Lupus. 1998;7 (Suppl 2):S144–S148. doi: 10.1177/096120339800700232. [DOI] [PubMed] [Google Scholar]
  11. Hellmann D. B., Petri M., Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 1987 Sep;66(5):341–348. doi: 10.1097/00005792-198709000-00002. [DOI] [PubMed] [Google Scholar]
  12. Knaus W. A., Draper E. A., Wagner D. P., Zimmerman J. E. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818–829. [PubMed] [Google Scholar]
  13. Rowan K. M., Kerr J. H., Major E., McPherson K., Short A., Vessey M. P. Intensive Care Society's APACHE II study in Britain and Ireland--II: Outcome comparisons of intensive care units after adjustment for case mix by the American APACHE II method. BMJ. 1993 Oct 16;307(6910):977–981. doi: 10.1136/bmj.307.6910.977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Seleznick M. J., Fries J. F. Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum. 1991 Oct;21(2):73–80. doi: 10.1016/0049-0172(91)90040-7. [DOI] [PubMed] [Google Scholar]
  15. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  16. Tucker L. B., Menon S., Schaller J. G., Isenberg D. A. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995 Sep;34(9):866–872. doi: 10.1093/rheumatology/34.9.866. [DOI] [PubMed] [Google Scholar]
  17. Ward M. M., Pyun E., Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum. 1995 Feb;38(2):274–283. doi: 10.1002/art.1780380218. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES